Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVersarien Share News (VRS)

Share Price Information for Versarien (VRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.065
Bid: 0.065
Ask: 0.072
Change: -0.004 (-5.52%)
Spread: 0.007 (10.769%)
Open: 0.07
High: 0.07
Low: 0.065
Prev. Close: 0.0725
VRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Revenue falls, losses widen for Versarien

Thu, 05th Aug 2021 13:36

(Sharecast News) - Advanced engineering materials company Versarien reported group revenues of £6.6m in its preliminary results on Thursday, down from £8.3m year-on-year.
The AIM-traded firm said it made an adjusted EBITDA loss of £1.8m in the year ended 31 March, widening slightly from £1.6m in the prior year.

Its reported loss before tax came in at £8.1m, compared to £4.7m, after a non-cash share=based payments charge in the year of £1.2m and a non-cash £3.3 million charge arising from a reduction in the IFRS 13 valuation of the Lanstead sharing agreement.

Cash at year-end totalled £2.4m, widening from £1.7m in the 2020 financial year.

During the year, the company reinvested an issue of 8.75 million ordinary shares into an 18-month sharing agreement with Lanstead Capital Investors, US-based institutional investor.

Net assets were £16.5m as at 31 March, up from £15.7m in the prior year.

Since the financial year ended, a £1.93m strategic investment was made in Versarien by Graphene Lab. including a 5% royalty agreement and a 2% trademark agreement on sales.

It also acquired Spain-based graphene manufacturing assets to provide up to an additional 100 tonne powder capacity per annum, and placed orders for the purchase of ink scale-up equipment to give up to an additional 12,000 litres of ink capacity per annum.

A lease had been signed on a new, dedicated graphene production facility in Longhope, Gloucestershire, and signed a textile supply agreement with Crosslete, with discussions ongoing with a number of garment suppliers.

Versarien had also signed an agreement with one of the world's largest packaging companies since the year ended, to evaluate graphene-based coatings.

"Despite the challenges arising from the pandemic, which not unexpectedly impacted our mature businesses, we have continued to focus on the commercialisation of our graphene technologies and in particular through the 'GSCALE' project," said chief executive officer Neill Ricketts.

"I am pleased to report that the manufacturing scale up is advancing in tandem with the progress on commercialisation of the project's applications.

"Highlights include the development and supply agreements for textiles and the number of infrastructure opportunities following the successful pourings of graphene enhanced concrete."

In addition, Ricketts said the company was working with multiple industrial partners to develop composite structures for automotive, aerospace, defence and rail.

"We have also demonstrated 40% improvement in concrete strength, 30% increase in tyre rubber stiffness and have applied to trademark 'GrapheneWear' as part of the textile commercialisation.

"With this we continue to pursue our strategy of global positioning to ensure that our products can be supplied to multiple sectors in multiple markets."

At 1550 BST, shares in Versarien were down 3.69% at 35.2p.
More News
1 Oct 2013 15:54

DIRECTOR DEALINGS: Versarien Finance Director Buys Shares, Granted Options

Read more
30 Sep 2013 09:49

Versarien Predicts PC Markets Shakeup With First Water-Cooled PC

Read more
27 Sep 2013 11:17

Versarien Loss Widened In Last Financial Year Before Transformation

Read more
27 Sep 2013 08:48

Friday broker round-up UPDATE

Admiral Group: Berenberg ups target price from 1060p to 1080p, but still recommends selling. Amlin: Berenberg reduces target price from 422p to 398p and downgrades to sell. Atkins (WS): JP Morgan increases target price from 1298p to 1348p and maintains an overweight rating. AZ Electronic Material

Read more
12 Jul 2013 08:11

Friday broker round-up UPDATE

Ashmore Group: Morgan Stanley cuts target price from 444p to 420p and leaves its equal-weight rating unchanged. JP Morgan ups target price from 339p to 377p maintaining a neutral rating. AstraZeneca: Jefferies reduces target price from 3560p to 3400p, while keeping its hold recommendation. Aviva:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.